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ABSTRACT 
Prostate cancer (PC) is a prominent killer; men over 40 should receive annual digital 
rectal exam (DRE) to prevent metastatic prostate cancer (MPC). For rare outcomes like MPC, 
case-control studies are common. Previous studies counted DREs as dichotomous and compared 
cases/controls using conditional logistic regression and the case-control odds ratio. 
Observation time for DRE ends at PC since afterwards DREs are diagnostic. Cases and 
controls are matched on time; but when cases are screen-detected there is bias counting more case 
screenings. Excluding tests shortly before diagnosis only reverses the bias. 
We begin instead with a life table for first DRE, stratified by case/control and propensity 
score (representing confounders), from which the Mantel-Haenszel odds ratio is calculated for 
case/control versus DRE on tables cross-classifying these, stratified by interval and propensity 
score. We find a mildly protective effect (OR=0.861, 95% CI=0.611,1.215), and find the 
approach superior to those used in previous studies. 
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1 CHAPTER ONE: INTRODUCTION 
Prostate cancer (PC) is the second leading cause of death due to cancer in North 
American men [1]. Men over the age of 40 are recommended to receive annual screening for PC. 
Digital rectal exam (DRE) has long been the standard method of screening for PC by general 
practitioners. The goal of DRE is not to prevent PC, but to detect it early enough to reduce the 
metastatic form of the disease (the spreading of the cancer throughout the body). Metastatic 
prostate cancer (MPC) almost always leads to death [2], and almost all deaths from prostate 
cancer result from the metastatic form. According to the U.S. National Cancer Institute in 2004, 
the estimated lifetime risk of PC is about 17.8%, and the lifetime risk of MPC is 3%. 
One way to study the efficacy of a screening test is through a randomized controlled trial. 
Such trials have been used to study various screening tests including mammography, clinical 
examination of the breast, sputum cytology among smokers, and fecal occult blood testing [3]. 
However, for a rare outcome, randomized trials require prohibitively large sample sizes to detect 
a moderate screening effect [3]. Cohort studies face the same problem. The case-control study is 
an alternative design that avoids this problem; by selecting every case in a specified region and 
then sampling an appropriate number of controls from the same population, reasonable power can 
be achieved with much smaller sample sizes. 
Previous case-control studies of DRE efficacy have found equivocal results in the 
protective direction. A 1998 study by Jacobsen et al [4] found a strong protective effect of DRE 
on prostate cancer mortality (OR=0.31; 95% CI=0.19-0.49). However, in studies by Richert-Boe 
et al [6] and Friedman et al [7], no significant association was found (OR=0.84 and 0.90, 
respectively), and in a 2004 case-control study of prostate cancer mortality and DRE screening by 
Weinmann et al [8], a protective but insignificant result was also seen (OR=0.70; 95% CI=0.46-
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1.1). These studies counted screening/no screening as a dichotomous variable, and analyzed 
whether the prevalence of this exposure differed between cases and controls. Methods of analysis 
varied from conditional logistic regression to the case-control odds ratio for 2 by 2 tables. Cases 
and controls are matched on the basis of observation time to ensure that each group had an equal 
opportunity to be screened. Often subjects are also matched on age and region of residence. The 
observation time for a case ends at the diagnosis of PC, since beyond that time no test would be 
screening, but rather diagnostic. But the observation time may end sooner if for example there is 
the onset of symptoms related to PC (e.g., urinary difficulties), since symptoms also make it 
likely that any testing is diagnostic. 
The problem with this approach arises when a case's PC is detected by a screening test 
(screen-detected case). The diagnosis of PC ends the observation time for the case—and also his 
matched controls, to produce a fair comparison. But the result is a bias favoring higher apparent 
screening rates in cases compared with controls [9]. To see this, consider an example in which 
screening will always detect PC if it's present, and cases and controls are screened at the same 
rate over time. The latter condition implies that there is no effect of screening on MPC, so an 
unbiased estimate should show no effect. Each matched set is observed exactly long enough to 
record the screening test for the case, and no longer. Whether the screening test occurred first for 
the case or for his matching control is a coin toss if they are screened at the same rate. The half of 
the controls who are screened after their matching cases will not have their test recorded, but all 
cases have theirs recorded. This bias is mitigated somewhat if screening is more frequent or if the 
sensitivity of the screening test is not perfect. Figure 1.1 and Figure 1.2 illustrate the bias. 
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Figure 1.1 In matched sets with no screen-detected case there is no dependence between screening 
tests in the cases and the end of the observation time in matched controls; if cases and 
controls are screened at the same rate all DREs are counted equally 
 
Figure 1.2 In matched sets with a screen-detected case there is dependence between screening tests in 
the cases and the end of the observation time in matched controls; if cases and controls 
are screened at the same rate all DREs are counted in cases but only half the DREs in 
controls are counted 
 
One solution that has been proposed [7] in an effort to eliminate this bias is the exclusion 
of all tests done within some time before the diagnosis. However, this introduces a bias in the 
opposite direction; amongst screen-detected cases, the test will always precede the diagnosis by a 
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short time, and all these tests will be excluded. The cases will be observed as long as possible to 
just miss recording the screening, which is as unfair as possible towards the cases having an 
opportunity to be screened. This strongly biases the result in favor of screening [7]. The strongly 
protective result found in the 1998 study by Jacobsen et al was based on this approach. Figure 1.3 
illustrates this reverse bias. 
Figure 1.3 In an effort to eliminate the dependence bias, all DREs a short time from diagnosis are 
excluded, but this reverses the bias; if cases and controls are screened at the same rate no 
DREs are counted in cases but half the DREs in controls are counted 
 
In this study, we propose an alternative method of analyzing case-control screening data 
that is free of these biases. The data are initially analyzed in a stratified life table survival analysis 
where first screening DRE is the event, stratified by case/control status and propensity score [14], 
a single variable representing the combination of several confounding variables. The overall 
Mantel-Haenszel odds ratio for case/control status versus DRE is calculated from the life tables 
on the set of 2 by 2 tables cross-classifying DRE with case/control status, stratified by interval 
and propensity score. This estimates the relative odds of DRE screening in cases versus controls 
[10], but since odds ratios are symmetric, it also estimates the effect of having a screening DRE 
on the odds of developing MPC. 
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In this project we apply this method to the study of DRE efficacy in preventing MPC. We 
examine the method both mathematically and using Monte Carlo simulation. 
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2 CHAPTER TWO: DATA COLLECTION 
2.1 Cases 
In a case-control study, data are first collected on some fraction (for rare diseases, this 
may be 100%) of the disease cases occurring within the study population during some period of 
time. In this project, the study population consisted of all residents of Metropolitan Toronto and 
the 5 surrounding counties of Durham, Halton, Peel, York and Simcoe. This can be described in 
terms of the following 8 regions: Halton, Peel, Simcoe, Etobicoke, City of York, York Region, 
Old Toronto, Durham, North York, Scarborough, East York. This describes a population of 5.2 
million (2001) and is served by two Regional Cancer Centres. Cases were men who developed 
metastatic prostate cancer between August 1, 1999 and May 31, 2002. Patients with metastases to 
the lymph nodes and those with local spread of the original tumor into adjacent organs were 
excluded. This is because this study is using MPC as a proxy for mortality from PC; thus MPC 
was strictly assessed as spread into bones and/or distant organs. Cases had to be 40 to 84 years of 
age when diagnosed with MPC, diagnosed with PC on or after January 1, 1990, living in the 
study area at the time of PC diagnosis and able to answer a questionnaire in English. The date of 
diagnosis of PC was the date of biopsy. 
New cases of MPC were found by searching computerized lists of PC patients treated at 
the two Regional Cancer Centres. To ascertain cases that were not referred to the Cancer Centres, 
monthly contacts were maintained by telephone, mail, or email with the participating urologists 
(88 out of 90) and all the oncologists in the study area who would normally treat men with MPC. 
There were 235 cases in the analysis dataset. 
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Charts were searched for screening DREs only between January 1, 1990 and the date of 
diagnosis of PC (henceforth this date may be referred to as the "reference date"). Prostate-related 
symptoms (e.g., urinary difficulties) were ascertained from the beginning of the patient history. 
Data were also collected on the matching variables age and geographic region, as well as several 
other variables that would be considered as potential confounders, including smoking history, 
alcohol consumption "about ten years ago" (around 1990) measured on an 8-point index, body 
weight, frequency of routine doctor checkups from 1980 to 1984 and from 1985 to 1989, 
frequency of strenuous activity between the ages of 30 and 39 and "about ten years ago" (around 
1990), whether a blood relative was ever diagnosed with prostate cancer, whether a blood relative 
was ever diagnosed with any other form of cancer, education, country of origin (born in Canada 
or elsewhere), and frequency of use of multivitamins during the past 20 years. 
2.2 Controls 
Controls were men without metastatic prostate cancer, selected randomly from the 
municipal tax records database for the study area and able to answer a questionnaire in English. 
There were 458 controls in total. Men known to have non-metastatic prostate cancer were eligible 
to be controls as long as their cancer was diagnosed after January 1, 1990. 11 controls developed 
prostate cancer during the study. Controls were sampled throughout the period of case accrual 
and frequency matched to cases for age group (5-year intervals) and region of residence (8 
regions). Because of difficulties encountered obtaining charts, the relative number of controls 
matched to the cases is not constant across strata, but this should not adversely affect the analysis. 
Controls were further "matched" on the basis of observation time to individual cases; their charts 
were searched for screening DREs only between January 1, 1990 and the date of diagnosis of PC 
for the matching case (the reference date). However, we will see that in the analysis performed in 
this study, the data can be treated as having been matched only on age group and region. Table 
2.1 shows the number of cases and controls in each stratum of the matching variables. 
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Table 2.1 Distribution of the matching variables age group (in 1990) and region in the study sample 
Region 
Age 
Group Cases Controls Region 
Age 
Group Cases Controls
Durham 40-44 1 3 
Scarborough/East 
York 55-59 6 16 
Durham 45-49 2 3 
Scarborough/East 
York 60-64 8 15 
Durham 50-54 4 8 
Scarborough/East 
York 65-69 12 19 
Durham 55-59 7 8 
Scarborough/East 
York 70-74 6 12 
Durham 60-64 4 17 Simcoe 35-39 1 2 
Durham 65-69 5 7 Simcoe 45-49 4 7 
Durham 70-74 3 7 Simcoe 50-54 3 4 
Etobicoke/City of 
York 45-49 2 3 Simcoe 55-59 3 8 
Etobicoke/City of 
York 50-54 3 10 Simcoe 60-64 2 6 
Etobicoke/City of 
York 55-59 7 14 Simcoe 65-69 6 7 
Etobicoke/City of 
York 60-64 6 16 York Region 35-39 2 4 
Etobicoke/City of 
York 65-69 11 15 York Region 40-44 2 6 
Halton/Peel 40-44 1 1 York Region 45-49 3 4 
Halton/Peel 45-49 1 4 York Region 50-54 5 7 
Halton/Peel 50-54 2 8 York Region 55-59 3 12 
Halton/Peel 55-59 14 19 York Region 60-64 9 12 
Halton/Peel 60-64 6 18 York Region 65-69 6 17 
Halton/Peel 65-69 9 17 York Region 70-74 3 3 
Halton/Peel 70-74 3 4 Old Toronto 40-44 1 2 
North York 45-49 1 2 Old Toronto 45-49 1 2 
North York 50-54 2 3 Old Toronto 50-54 4 6 
North York 55-59 5 9 Old Toronto 55-59 6 9 
North York 60-64 8 18 Old Toronto 60-64 9 20 
North York 65-69 8 17 Old Toronto 65-69 6 14 
Scarborough/East 
York 45-49 3 5 Old Toronto 70-74 4 5 
Scarborough/East 
York 50-54 2 3     
Besides the matching variables age group and region, the same potential confounding 
variables that were collected on the cases were also collected on the controls. 
 
 8
3 CHAPTER THREE: STATISTICAL ANALYSIS 
3.1 Propensity score 
3.1.1 Background 
Propensity scoring is a method of combining several variables into a single continuous 
measure for the purpose of adjusting for the original variables as potential confounders in the 
analysis of some treatment [14]. This approach is useful when the data are too sparse to adjust for 
the confounding variables simultaneously via inclusion in the model. The propensity score is the 
estimated probability of a subject having the treatment level of interest given his set of potential 
confounders. It is often estimated with logistic regression. 
When using logistic regression to analyze matched data, failure to condition on the 
matching variables can lead to bias or instability [19]. The former problem can arise if one 
applies an unstratified analysis, while both problems can arise if one uses an unconditional 
likelihood and represents strata with design variables, in part because there are often too few 
subjects within each stratum to facilitate the estimation of stratum-specific parameters. 
The correct approach for matched data analysis is conditional logistic regression (CLR). 
Hosmer and Lemeshow [19] explain CLR maximum likelihood estimation as maximizing a 
likelihood that is, for the  stratum, the probability of the observed data conditional on the 
Stratum k total  and number of cases , which are the sufficient statistic for the stratum-
specific (nuisance) parameters. This is the likelihood of the data in Stratum k divided by the sum 
of the probabilities over the  possible assignments of cases and controls within Stratum k 
under the observed number of cases. Conditioning on the sufficient statistic removes the 
thk
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Note that the probabilities in this expression are of the observed covariate vectors 
conditional on the outcome, case/control status. This is the right direction for case-control data, in 
which the disease outcome is fixed and the covariates are random. 
Goodness of fit for a regression model can be tested with the likelihood ratio test (LRT) 
comparing the likelihood under a p-parameters restricted model  with that under a larger m-
parameters model that is presumed correct, . The smaller model should be nested within the 
larger model. The LRT test statistic is: 
RL
FL
( )FRpm LLlog22 −=−χ  
which is chi-square with m-p degrees of freedom under the null hypothesis that the smaller model 
fits the data as well as the larger. 
A measure of predictive utility for a regression model is Akaike's information criterion 
(AIC). It is defined as 
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pLAIC 2)log(2 +−=  
where there are p parameters in the model. AIC is maximum log likelihood adjusted for over-
fitting—it penalizes the likelihood for including too many variables in a model. The idea of AIC 
is to estimate how well a model will predict the outcome in new data. Lower AIC indicates better 
predictive utility. 
3.1.2 Calculating propensity score in the DRE study 
In the DRE study, the first stage of analysis will involve considering case/control status 
as the explanatory variable and screening DRE as the outcome; the distribution of time to first 
screening DRE will be compared between cases and controls in a stratified life table. For this 
reason, the propensity score must be the estimated probability of caseness given a set of potential 
confounders. This is estimated in a binary conditional logistic regression model with case/control 
status as the dependent variable, conditioning on the matching variables age group and region. 
Recall that the controls were "matched" to cases also on observation time, that is, controls were 
only observed for DRE up to the reference date for a case. This need not be considered matching 
for this part of the analysis, however, because case/control status was determined at the end of the 
study regardless of reference date, and the potential confounders were measured at the start of the 
study. Therefore for this stage of the analysis, all subjects were observed equally. Age group and 
region are to be conditioned on as they were true matching variables guiding sample selection. 
The variables to be considered as potential confounders were selected from a larger pool 
of available variables under the guidance of the lead epidemiologist. They were those variables 
that had some scientific basis for possibly acting as confounders in this analysis. For example, in 
order to act as a confounder, a variable needs at least to be related to both the explanatory 
variable (screening DRE) and the outcome (caseness, or MPC). The set of potential confounders 
selected for consideration in this study included smoking history, alcohol consumption "about ten 
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years ago" (around 1990) measured on an 8-point index, body weight, frequency of routine doctor 
checkups from 1980 to 1984 and from 1985 to 1989, frequency of strenuous activity between the 
ages of 30 and 39 and "about ten years ago" (around 1990), whether a blood relative was ever 
diagnosed with prostate cancer, whether a blood relative was ever diagnosed with any other form 
of cancer, education, country of origin (born in Canada or elsewhere), and frequency of use of 
multivitamins during the past 20 years. 
The propensity score model is a conditional logistic regression model with case/control 
status as the outcome and the confounders as the explanatory effects, conditioning the likelihood 
on the matching variables age group and region. First the full model was fit with all potential 
confounders. The selection strategy proceeded by dropping each variable from the full model in 
turn and assessing AIC for each smaller model. The one variable that had the most beneficial (or 
least detrimental) effect on the AIC when dropped from the full model was chosen to be dropped 
in the step 1 model. The reduced (by one variable) set of confounders then became the reference 
set from which each remaining variable was again dropped one at a time. AIC formed the basis 
for deciding which single variable to drop from that reduced set, to form the step 2 model. This 
process was repeated until all the variables were eventually dropped from the model. At each step 
a LRT was performed to test whether the sub-model fit the data as well as the original, full model. 
The final set of confounders selected came from the selected model with the lowest AIC. 
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Table 3.1 Model AIC and likelihood ratio tests in the development of the propensity score 
Step Dropped AIC -2Log(L) 
Model 
d.f. 
LRT 
Chi-
square LRT d.f. 
LRT p-
value 
0  639.58 579.58 30    
1 
Strenuous 
activities 10 
years ago 633.36 581.36 26 1.78 4 0.776 
2 Education 627.97 585.97 21 6.39 9 0.701 
3 
Routine 
checkups 
1985-1989 623.03 589.03 17 9.45 13 0.738 
4 
Strenuous 
activities age 
30-39 618.12 592.12 13 12.54 17 0.766 
5 Smoking 614.73 592.73 11 13.15 19 0.831 
6 Multivitamins 615.88 597.88 9 18.30 21 0.630 
7 
Relative with 
other cancer 617.13 601.13 8 21.55 22 0.487 
8 
Born in 
Canada 618.77 604.77 7 25.19 23 0.341 
9 
Routine 
checkups 
1980-1984 624.12 618.12 3 38.54 27 0.070 
10 Body weight 631.19 627.19 2 47.61 28 0.012 
11 Alcohol 646.87 644.87 1 65.29 29 0.000 
 
 13
 Figure 3.1 Model AIC at each step in the development of the propensity score 
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Table 3.1 shows which variable was dropped at each step of the model selection, and 
provides the AIC and LRT results. Figure 3.1 plots the AIC for each step of the model selection. 
Step 5 is the model that produces the lowest AIC. The LRT shows that the model fits as well as 
the full model. The final set of confounders is therefore whether a blood relative was ever 
diagnosed with prostate cancer, whether a blood relative was ever diagnosed with any other form 
of cancer, frequency of use of multivitamins during the past 20 years, country of origin (born in 
Canada or elsewhere), frequency of routine doctor checkups from 1980 to 1984, body weight, and 
alcohol consumption "about ten years ago" (around 1990) measured on an 8-point index. 
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Table 3.2 Final propensity score model 
Variable Level Estimate 
Standard 
error 
Wald chi-
square P-value 
Odds 
Ratio 
Body weight  0.009 0.003 7.577 0.006 1.009 
Relative with 
other cancer  -0.001 0.002 0.215 0.643 0.999 
Relative with 
prostate cancer  -0.006 0.002 6.393 0.011 0.994 
Born in Canada  -0.147 0.187 0.616 0.433 0.864 
Alcohol  -0.001 0.041 0.000 0.988 0.999 
Yes 
irregularly 0.450 0.225 3.986 0.046 1.569 
Multivitamins 
during past 20 
years 
(reference=never) 
Yes 
regularly -0.107 0.235 0.208 0.648 0.898 
Once in 5 
years -0.283 0.324 0.760 0.383 0.754 
Once each 
2-4 years -0.172 0.293 0.345 0.557 0.842 
Once per 
year -0.804 0.270 8.866 0.003 0.447 
Routine checkups 
1980-1984 
(reference=never) 
More than 
once per 
year -0.566 0.342 2.742 0.098 0.568 
 
Table 3.2 shows the conditional logistic regression model coefficients for the final model. 
Note that in conditional logistic regression no intercept terms are estimated. In a case-control 
study, since it is under the investigators' control how many cases and controls to sample, the data 
contain no information about baseline risk; the propensity score from this model for each subject 
is the probability of caseness only within the selected sample, not the general population. As a 
propensity score, this will suffice; it is the relative probabilities between subjects with different 
confounder vectors that is the important aspect of a propensity score that allows it to provide an 
adjustment for the set of confounders, when stratified upon. The relative probabilities are 
approximately preserved even without information on baseline risk. 
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Fifty-three subjects had one or more missing covariates. These subjects were assigned the 
median value of the missing variable(s) in order to calculate a propensity score for them. In most 
cases there was only a single missing variable. 
Finally, the propensity score was categorized into three levels according to tertiles. This 
would allow it to be stratified upon in subsequent analyses without problems of sparse strata. 
3.2 Life table analysis 
Life table analysis is a method of analyzing survival (or time to event) data. The next step 
in the DRE study is to compare the distributions of time to first DRE screening between cases and 
controls using the life table method. The reason “first DRE” is the event rather than, for example, 
“first DRE that detects PC” is that the difference in exposure distributions is desired between 
cases and all controls, not just between cases and those controls who were diagnosed with 
prostate cancer during the course of the study. The question is whether cases have different rates 
of screening DRE than controls, and in advance of knowing the results of a screening DRE, all 
screening DREs may be considered equal. 
3.2.1 Background 
In survival data, there are observed event times and censored observations. A right-
censored observation is one in which a subject ceases to be observed before the event is recorded; 
for such a subject it is only known that the event occurred sometime after the censoring time. A 
left-censored observation is one in which a subject does not begin to be observed until after the 
event has already occurred; for such as subject it is only known that the event occurred sometime 
before the censoring time. In a life table analysis the data are made up of observed event times 
and right-censored times. 
The first step is to split the time axis into k intervals of generally equal length. If data are 
overly sparse then later intervals may be made longer. Selecting intervals is somewhat subjective. 
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In deciding the number and width of the intervals, the precision of the estimates can be a guide; 
intervals that are too short may not contain enough events to produce precise estimates of survival 
probability. On the other hand, if the intervals are too broad one can lose important information 
about changes in the survivor function over time. 
Lawless [16] provides an overview of the life table method and theory for usual, 
prospective data. The following explanation is drawn largely from that source. 
Let  denote the number of events in interval j,  the number of subjects still being 
observed at the start of interval j (not yet failed or censored by that point), and  the number of 
subjects censored in interval j. Then the likelihood of the data is: 
jD jN
jW
( )( ) ( )( )∏
=
k
j
jjj jDWPjDP
1
,|| HH  
where ( ) ( )1111 ,,...,, −−= jj WDWDjH  is the vector containing all the information about what 
happened prior to interval j. The likelihood is developed under a special case where all censoring 
occurs at interval endpoints. The number of events in each interval j is assumed to be Binomial 
and not depend on censoring within the interval: 
( )( ) ( )jjj qNjDP ,Binomial~| H  
This is reasonable since all censoring occurs at interval endpoints, and can only occur among 
those subjects who did not fail by that point. If the terms ( )( )jDWP jj H,|  do not contain 
information about the parameters , then they can be dropped from the likelihood to give: jq
( ) ( )∏
=
−−⎟⎟⎠
⎞
⎜⎜⎝
⎛=
k
j
DN
j
D
j
j
j
k
jjj qq
D
N
qqL
1
1 1,...,  
In a stratified life table analysis, the likelihood is maximized within each stratum. 
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This likelihood was developed for prospective data, but we wish to apply it to our 
retrospective data, and stratify the life table according to case/control status. The question is 
whether this is a valid approach. Were we to have analyzed the time to disease outcome amongst 
the cases stratified by one or more (in this case random) covariates, this might prove more 
difficult to answer. However, our life table is stratified by the fixed quantity case/control status, 
and the event time being modeled is the random "covariate" time to first screening DRE. 
Therefore this likelihood, like the conditional logistic regression likelihood in the previous 
section, is already in the right direction for our retrospective data. 
Continuing Lawless's derivation, we take the log and solve the likelihood equations to 
yield the MLE: 
jjj NDq =ˆ  
Conditional expectation can be used to obtain the (diagonal) Fisher information matrix: 
( )( ) ( )( )jj jjj qq
NE
I −= 1q  
Finally, taking the inverse and estimating ( )jNE  with  gives an asymptotic diagonal 
covariance matrix for q : 
jN
ˆ
( )( ) ( )
j
jj
jj N
qq ˆ1ˆ
ˆRAˆASV
−=q  
The above was developed under the special case where all censoring occurs at interval 
endpoints. In reality, there is usually a censoring process that is assumed to run independently of 
and compete with the survival process, and therefore censoring times can occur anywhere in an 
interval. The standard life table estimator for  is actually jq
'ˆ jjj NDq =  
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where  is the "effective sample size" in interval j. This is based on the idea that 
if the average censoring time within an interval is approximately at the midpoint, then each 
censored observation only had about half the time to fail as did one that was observed throughout 
the interval. In general,  is not a consistent estimator of . However, according to Lawless, if 
censoring is fairly evenly distributed throughout an interval and not too heavy, and the intervals 
are not too wide, then the life table estimates can be considered acceptable. 
jjj WNN 5.0
' −=
jqˆ jq
Now let  denote the probability of survival beyond interval j (not having an event 
before the end of interval j). This is the survivor function evaluated at the endpoint of interval j. 
To survive beyond interval j, one must not experience an event in any interval up to and including 
interval j. Therefore: 
jP
( )∏
=
−=
j
i
ij qP
1
1  and . ( )∏
=
−=
j
i
ij qP
1
ˆ1ˆ
Since  is not a consistent estimator of , neither in general is  a consistent estimator of 
. The life table variance estimate is based on limiting multivariate normal distributions with 
mean 0 of 
jqˆ jq jPˆ
jP
( )*ˆ PP −n  and ( )*ˆ qq −n , application of the multivariate delta formula 
( ) ( )( ) ( )∑∑
= = ∂
∂
∂
∂=
k
i
k
j
ji
ji
kk TT
ggTTgTTg
1 1
21
1211 ,ASCOV,...,,,...,ASCOV θθ , 
where  are statistics and iT
( ) ( )∑⎯→⎯−− ,,...,11 0NTTn Dkk θθ , 
and substitution of  and  with q  and . This gives Greenwood's formula: *q *P ˆ Pˆ
( ) ( )∑= −=
j
i ii
i
jj qN
qPP
1
'
2
ˆ1
ˆˆˆRAˆASV  
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This result will be used to provide confidence intervals for the life table estimates. 
3.2.2 Setting up the life table in the DRE study 
To begin the life table analysis in the DRE study, 2-year intervals were selected for time 
to first screening DRE, with left boundaries ranging from 0 to 4 years, and a final longer interval 
from 6 to 12 years. The latter interval was made longer in order to ensure adequate data in the 
fully stratified analysis. 
In this study, event times were censored if any of the following conditions occurred 
before a subject had a screening DRE: diagnosis of prostate cancer in the subject, or for a control, 
diagnosis of PC in his matching case (the reference date); onset of prostate-related symptoms; 
positive PSA (prostate specific antigen) test result (defined as PSA level >4.0); or any TRUS 
(transrectal ultrasound) performed. Event times for controls were censored at the reference date 
because during the data collection they were only observed up to that point in their charts, while 
the latter three conditions were considered censoring events because any DRE test performed 
after their occurrence was likely to be diagnostic instead of screening. It is reasonable to view 
these censoring processes as independent of the screening DRE event process. 
3.2.3 Life table stratified only by case/control status 
The first life table is stratified only by case/control status. Survivor functions for cases 
and controls are listed in Table 3.3 and plotted along with lower and upper 95% confidence limits 
in Figure 3.2. The higher survivor function in cases suggests that they had a lower rate of 
screening DREs than controls, indicating a protective effect of DRE screening. The case survivor 
function lies partially above and partially below the upper 95% confidence limit for the controls, 
suggesting that the difference between survivor functions might be only borderline statistically 
significant. However, this life table is not adjusted for the matching variables or potential 
confounders, so we must expand the stratification. 
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Table 3.3 Life table analysis of time to first screening DRE stratified by case/control status 
Case/ 
Control 
Lower 
Time 
Upper 
Time 
(UT) # Failed 
# 
Censored 
Effective 
Sample 
Size 
Survivor 
Function 
S(UT) 
Standard 
Error 
0 2 79 163 376.5 0.79 0.021 
2 4 48 37 197.5 0.598 0.029 
4 6 27 25 118.5 0.462 0.032 
Controls 
6 12 18 61 48.5 0.29 0.038 
0 2 38 62 204 0.814 0.027 
2 4 23 22 124 0.663 0.036 
4 6 13 21 79.5 0.554 0.041 
Cases 
6 12 18 38 37 0.285 0.05 
 
Figure 3.2 Life table survivor functions for time to first screening DRE stratified by case/control 
status, with 95% confidence limits 
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3.2.4 Life table stratified by case/control status and collapsed matching variables 
age group and region 
Next we adjust the life table for the matched design. Recall that cases and controls were 
matched on age group with 5-year intervals and region with 8 regions. Subsequent stages of the 
DRE analysis will require data for both cases and controls in each stratum of the stratified life 
table. For this reason, the stratification by the matching variables had to be done on collapsed 
variables. Age group was dichotomized into two groups, 35-59 (n=293) and 60-74 (n=400). 
Region was collapsed into three geographically contiguous areas: Halton/Peel and Simcoe 
(n=160); Etobicoke/City of York, York Region and Old Toronto (n=274); and Durham, North 
York and Scarborough/East York (n=259). There are 6 strata besides case/control status. 
Survivor functions for cases and controls within each of the 6 strata are plotted along 
with lower and upper 95% confidence limits in Figure 3.3. Cases show lower or equal rates of 
first screening DRE than controls in all but one stratum; in Halton/Peel and Simcoe ages 35-59, 
the effect is reversed, and the confidence limits suggest that the difference might be borderline 
significant. In Halton/Peel and Simcoe ages 60-74, the graph suggests borderline statistical 
significance for the opposite and prevailing effect (controls showing higher rates of screening). 
Possible statistical significance of the prevailing effect can also be seen in the stratum of Durham, 
North York and Scarborough/East York ages 35-59, and the stratum of Etobicoke/City of York, 
York Region and Old Toronto ages 35-59. Overall, the graph suggests a protective effect of DRE 
screening against MPC. However, the life table has not been adjusted for the propensity score. 
The stratification must be taken one step further. 
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Figure 3.3 Life table survivor functions for time to first screening DRE stratified by case/control 
status and collapsed matching variables age group and region, with 95% confidence 
limits 
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3.2.5 Life table fully stratified by case/control status, the collapsed matching 
variables age group and region, and 3-level propensity score 
Finally, we fully stratify the life table by case/control status, the collapsed matching 
variables age group and region, and the 3-level categorical propensity score. 
Figure 3.4 Life table survivor functions for time to first screening DRE fully stratified by case/control 
status, the collapsed matching variables age group and region, and 3-level propensity 
score; the upper two graphs show the individual survivor functions; the lower graph 
shows the mean survivor functions with t-based (17 d.f.) 95% confidence limits 
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There are 18 strata in this life table besides case/control status. The survivor functions for 
the individual strata are plotted along with mean survivor functions and t-based (17 d.f.) 95% 
confidence limits for controls and cases in Figure 3.4. As seen in the previous two life tables, 
cases show a lower rate of first screening DRE than controls. The confidence limits indicate 
possible statistical significance, but this is informal. Formal tests are performed in the next 
section. 
3.3 Stratified Mantel-Haenszel odds ratio 
The next step in the DRE study is to reduce the stratified life table into a single overall 
measure of effect. This is accomplished with the Mantel-Haenszel odds ratio. 
3.3.1 Background 
Suppose there are data that have been stratified into k strata, with a 2 by 2 table for each 
stratum cross-classifying a dichotomous outcome (e.g., a disease) with a dichotomous 
explanatory variable (e.g., a prophylactic). 
Table 3.4 Example 2 by 2 table for stratum j 
Disease / Prophylactic Prophylactic + (X=1) Prophylactic – (X=0) Total 
Disease + (Y=1) 
jn11  jn12  jn +1  
Disease – (Y=0) 
jn21  jn22  jn +2  
Total 
jn 1+  jn 2+  jn ++  
Table 3.4 illustrates this example for stratum j. The odds ratio for the relative odds of 
disease (Y=1) between prophylactic users (X=1) and nonusers (X=0) is 
( ) ( )( )
( ) ( )( )0|110|1
1|111|1
==−==
==−===
XYPXYP
XYPXYPθ  
The odds ratio estimator for the stratum j 2 by 2 table is developed as 
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( ) ( )( )
( ) ( )( ) ( ) ( )( ) ( ) ( )( )jj jjjjjj jjjj nn
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nnnn
nnnn
XYPXYP
XYPXYP
2112
2211
222212
121111
0|1ˆ10|1ˆ
1|1ˆ11|1ˆˆ ====−==
==−===
++
++θ  
An important property of the odds ratio is symmetry, that is, the relative odds of the 
higher level of one variable between the two levels of the other is the same regardless of which 
variable is viewed as the outcome. To see this, consider: 
( ) ( )( )
( ) ( )( )
( ) ( )
( ) ( )
( ) ( )( ) ( )
( )
( )
( ) ( )( ) ( )
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( ) ( )
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⎤⎢⎣
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θ
θ
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0|00|1
1|01|1
0
00|0
0
11|0
1
00|1
1
11|1
0|00|1
1|01|1
0|110|1
1|111|1
 
This property will be important to the later stages of the analysis. 
The asymptotic variance of the log odds ratio is derived in Agresti [12] using the delta 
method to be: 
( )( ) ⎟⎟⎠⎞⎜⎜⎝⎛ +++= 22211211 1111ˆlogˆ nnnnraV θ  
This can be used to construct a 95% normal-based confidence interval for the log odds ratio, 
which translates when the limits are exponentiated into a 95% confidence interval for the odds 
ratio: 
( ) ( )( )⎥⎦⎤⎢⎣⎡ ± θθ ˆlogˆˆlogexp 025. raVZ  
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The Mantel-Haenszel odds ratio [18] is an estimator for a single common odds ratio 
across k strata: 
( )
( )∑
∑
=
++
=
++
= k
j
jjj
k
j
jjj
MH
nnn
nnn
1
2112
1
2211
θˆ  
This estimator weights larger strata more heavily. The asymptotic variance of the log Mantel-
Haenszel odds ratio was developed by Robins et al [22] and given in Agresti [18]: 
( )( ) ( ) ( )
( ) ( )[ ]∑
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= ++
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where kkkj nnnR ++= 2211 , kkkj nnnS ++= 2112 , , , and ∑
=
=
k
j
jRR
1
∑
=
=
k
j
jSS
1
SR=θˆ . The 
estimator is considered valid under standard as well as sparse asymptotics in which k increases 
with n. The result depends in part on the assumption of independence between probabilities of 
exposure in cases and controls of different 2 by 2 tables. 
An important question to consider when calculating the Mantel-Haenszel odds ratio is 
whether there really is one common odds ratio across strata. The first way one might approach 
this question is by looking at a graph plotting the probabilities in the two treatment groups across 
strata. If the lines cross or their relationship otherwise differs substantially between strata then 
homogeneity of the odds ratio may not be a reasonable assumption. The Breslow-Day test [13] 
for homogeneity of odds ratios across strata can answer the question more formally. The test 
statistic for the null hypothesis of a single common odds ratio across k strata is: 
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which is referred to a chi-square distribution with k-1 degrees of freedom. This test requires a 
large enough sample size in each stratum that at least 80% of the expected cell counts are 5 or 
greater. Note that the existence of a common odds ratio is not a prerequisite for the Mantel-
Haenszel odds ratio. If no common odds ratio exists across strata, the Mantel-Haenszel odds ratio 
still provides an estimate of overall effect; in that case it simply should be understood that the 
effect is not meant to uniformly represent all members of the population. 
3.3.2 Calculating an overall measure of effect from a stratified life table 
The method of combining intervals from a stratified (two treatment groups) life table into 
a single odds ratio to estimate a treatment effect is explained by Kahn and Sempos [17]. The 
general approach treats the intervals in the life table as different strata, despite the violation of 
independence presented by the fact that all the subjects in any interval certainly occupied all 
previous intervals. Mantel [15] provided the theoretical justification for treating life table 
intervals as separate strata in order to calculate an overall test of significance for the difference 
between survivor functions. He used the construction of orthogonal (independent) variables to 
show that the Mantel-Haenszel chi-square (1 d.f.) test statistic for testing the overall significance 
of a set of 2 by 2 tables could also be used to compare life table curves: 
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where the k strata are the life table intervals and 
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are the expectation and variance of a hypergeometric random variable obtained under the null 
hypothesis and fixed table margins. 
The asymptotic variance of the log Mantel-Haenszel odds ratio is no longer valid because 
of the dependence between tables. Instead, confidence limits for the Mantel-Haenszel odds ratio 
can be obtained from Miettinen's test-based limits as explained by Kahn and Sempos [11]. The 
idea is to consider that the Mantel-Haenszel chi-square statistic above could alternatively have 
been obtained by: 
( ) ( )( )[ ]( )( ) ( )[ ]( )( )MHMHHMH MHMH VarVar E θθθ θθχ ˆlog 0
ˆlog
ˆlog
ˆlogˆlog
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1
0
−=−=  
This equation can be solved for the variance of the log Mantel-Haenszel odds ratio. This variance 
estimate can be used to obtain confidence limits using the usual standard normal quantiles. Kahn 
and Sempos point out that although the estimate is strictly valid only under the null hypothesis, 
they quote a study by Greenland that indicates reasonableness of the estimate except under the 
most extreme departures from the null (odds ratio>10.0 or <0.10). 
The first step in the procedure is to produce a 2 by 2 table from each life table interval, 
cross-classifying treatment group with failure indicator. Subjects who fail within an interval 
contribute to the failure cell for their treatment group in that interval's 2 by 2 table, while subjects 
surviving beyond an interval contribute to the survival cell for their treatment group. Subjects 
censored in an interval contribute 0.5 to the survival cell, consistent with the effective sample size 
calculation. Only subjects still at risk at the start of an interval contribute to that interval's 2 by 2 
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table. Each interval is treated as a separate stratum and the Mantel-Haenszel odds ratio is 
calculated. If there are additional variables (besides the treatment group) on which the life table 
was stratified, the combination of those variables with interval number forms the strata. The 
Mantel-Haenszel odds ratio estimates the overall effect of treatment on the odds of the outcome 
whose event time was modeled in the life table. 
In the following sections, the stratified life tables obtained earlier will be analyzed with 
the Mantel-Haenszel odds ratio. This will estimate the effect of being a case on the odds of 
having a screening DRE. However, since odds ratios are symmetric, it also estimates the effect of 
having a screening DRE on the odds of caseness; this is the study objective. The statistical 
significance of overall differences will be assessed with the Mantel-Haenszel chi-square test and 
test-based confidence limits will be produced. 
3.3.3 Calculating an overall effect from the life table stratified only by case/control 
status 
First we calculate an overall effect from the life table stratified only by case/control 
status. This life table was shown in Table 3.3. There are 4 intervals and therefore 4 2 by 2 tables 
to be constructed from the life table, each cross-classifying case/control status with screening 
DRE. Table 3.5 shows the 2 by 2 table created for the interval [4,6 years) from the stratified life 
table shown in Table 3.3. The individual odds ratio for this 2 by 2 table is 0.663 with 95% 
confidence interval (0.318, 1.379). 
Table 3.5 The 2 by 2 table for the interval [4,6 years) from the stratified life table shown in Table 3.3
Case/control status Screening DRE in the 
interval 
No screening DRE by 
the end of the interval 
Total at risk (effective 
sample size) 
Controls 27 91.5 118.5 
Cases 13 66.5 79.5 
Total 40 158 198 
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Before calculating the Mantel-Haenszel odds ratio, we might consider whether there is 
evidence against the existence of a common odds ratio. Figure 3.2 shows that the survivor 
functions do not cross, and the gap does not vary much except out at 12 years where the curves 
meet. The sample size in this life table is sufficient to use the Breslow-Day test for homogeneity 
of odds ratios, so we can test more formally. The chi-square test statistic is 2.93 on 3 degrees of 
freedom (p-value=0.403); there is no evidence against the existence of a common odds ratio. 
The Mantel-Haenszel odds ratio is 0.840 with 95% test-based confidence interval (0.617, 
1.143). The Mantel-Haenszel chi-square test statistic is 1.232 (p-value=0.267). Unadjusted for 
matching variables or confounders, there is little statistical evidence of a mild protective effect of 
having a screening DRE on the odds of developing MPC, and only in terms of the confidence 
interval leaning towards the protective side of null. The evidence is nowhere near strong enough 
to reject the null hypothesis at any reasonable alpha level. 
3.3.4 Calculating an overall effect from the life table stratified by case/control 
status and collapsed matching variables age group and region 
Next we calculate the Mantel-Haenszel odds ratio from the life table that was adjusted for 
the matching variables. This stratification produced 6 strata besides case/control status, and with 
4 intervals in each stratum, the Mantel-Haenszel odds ratio is based on 24 2 by 2 tables. Table 3.6 
shows the distribution of 2 by 2 table sizes. 
Table 3.6 Distribution of 2 by 2 table sizes from the matched life table analysis 
Effective 
sample 
size 
Number 
of tables 
Effective 
sample 
size 
Number 
of tables 
Effective 
sample 
size 
Number 
of tables 
Effective 
sample 
size 
Number 
of tables 
8.5 1 31.5 1 53.5 1 79.5 1 
14.5 1 34 1 56.5 1 102 1 
15 2 35 1 61 1 128 1 
15.5 1 37 2 66.5 1 135 1 
17 1 38 1 67.5 1   
22.5 1 46 1 69.5 1   
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The sample sizes appear to be sufficient to apply the Breslow-Day test for homogeneity 
of odds ratios. The chi-square test statistic is 24.51 on 23 degrees of freedom (p-value=0.376); 
there is no evidence against the existence of a common odds ratio. 
The Mantel-Haenszel odds ratio is 0.848 with 95% test-based confidence interval (0.621, 
1.156). The Mantel-Haenszel chi-square test statistic is 1.088 (p-value=0.297). After adjusting for 
the matching variables, there is even less evidence of a mild protective effect of having a 
screening DRE on the odds of developing MPC. 
3.3.5 Calculating an overall effect from the life table fully stratified by case/control 
status, the collapsed matching variables age group and region, and 3-level 
propensity score 
Finally, we calculate the Mantel-Haenszel odds ratio from the life table fully stratified by 
case/control status, the collapsed matching variables age group and region, and 3-level propensity 
score to adjust for confounders. This stratification produced 18 strata besides case/control status, 
and with 4 intervals in each stratum, the Mantel-Haenszel odds ratio is based on 72 2 by 2 tables. 
Table 3.7 shows the distribution of 2 by 2 table sizes. 
Table 3.7 Distribution of 2 by 2 table sizes from the fully stratified life table analysis 
Effective 
sample 
size 
Number 
of tables 
Effective 
sample 
size 
Number 
of tables 
Effective 
sample 
size 
Number 
of tables 
Effective 
sample 
size 
Number 
of tables 
2 1 10.5 1 18 1 26 1
2.5 3 11.5 2 20 1 30 1
3.5 2 12 3 21 1 30.5 1
4.5 2 12.5 3 21.5 1 35.5 1
5 3 13 3 22 2 36 2
5.5 2 13.5 1 22.5 2 40.5 1
6 3 14 3 23 1 42.5 1
7 2 14.5 2 23.5 2 43.5 1
7.5 4 16 3 24 2 48.5 1
9.5 2 17 1 24.5 2 52 1
Table sizes range from 2 to 52 (effective sample size). This degree of stratification has 
created sparseness: many tables have empty columns, and overall table sizes are generally small. 
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Fortunately, the Mantel-Haenszel odds ratio is designed to combine sparse data such as these into 
a stable estimate of a common effect. 
Is there a common odds ratio? Considering the effect across intervals, the mean survivor 
function curves in Figure 3.4 tell a similar story to when the life table was stratified only by 
case/control status; recall that in that situation no evidence was found against a common effect. 
However, in this case, the stratification of the Mantel-Haenszel odds ratio is across 72 2 by 2 
tables, with strata formed not only on interval, but also on the collapsed matching variables and 
the 3-level propensity score. Visually, there is no realistic way to ascertain homogeneity of odds 
ratios, and the Breslow-Day test cannot be applied due to the small table sizes. Instead, we 
perform another stratified life table analysis, only on 3-level propensity score without stratifying 
by matching variables, solely for the purpose of helping us assess homogeneity of odds ratios in 
the fully stratified analysis. The simpler analysis does produce sufficient table sizes to apply the 
Breslow-Day test. The chi-square test statistic is 6.98 on 11 degrees of freedom (p-value=0.801); 
there is no evidence against the existence of a common odds ratio across propensity score levels. 
We proceed under the assumption that stratifying on the matching variables and propensity score 
together will not alter the homogeneity of odds ratios found when stratifying on either alone, and 
calculate the Mantel-Haenszel odds ratio. 
The Mantel-Haenszel odds ratio is 0.861 with 95% test-based confidence interval (0.611, 
1.215). The Mantel-Haenszel chi-square test statistic is 0.722 (p-value=0.396). After adjusting for 
the matching variables and confounders together, the already weak evidence of a mild protective 
effect of having a screening DRE on the odds of developing MPC is even weaker. 
3.4 Results 
The Mantel-Haenszel odds ratio describing the overall effect of having a screening DRE 
on the odds of developing MPC, after adjusting for the matched case-control design as well as 
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several potentially confounding variables, was found to be 0.861 with 95% confidence interval 
(0.611, 1.215). This is based on a Mantel-Haenszel chi-square test p-value of 0.396. Like most of 
the other studies on DRE efficacy before this one (with the exception of the Jacobsen et al paper 
that was biased) the estimate is mildly protective but not statistically significant. 
This study finds only weak evidence of a mild protective effect of screening with digital 
rectal exam in the prevention of metastatic prostate cancer. 
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4 CHAPTER FOUR: SIMULATION 
The methodology outlined in this report is novel and therefore demands scrutiny. In the 
previous chapter, we endeavored to justify each step from a theoretical standpoint. In this chapter, 
we assess the validity of the method using Monte Carlo simulation programmed in SAS 9.1.3. 
4.1 Building the population 
The first step in studying this method by simulation is to construct an artificial population 
from which a case-control sample can be drawn, matching the DRE study population as closely as 
possible. 
To determine the appropriate size of the simulated population, we must estimate the 
proportion of the actual population in-scope for the DRE study as those data were collected 
(between August 1, 1999 and May 31, 2002, centered at the beginning of 2001). This is defined 
as male, aged 35-74 in 1990, which describes 19.8% of the 2000/2001 Ontario population. (Note 
that age is defined in 1990. This is to provide a common frame of reference; since the data were 
collected over 2 years, age at time of data collection would not define a coherent population.) The 
total population in the 6 study counties as of the 2001 Canadian census was 5.19 million, or about 
1.0 million in-scope men. The simulated population therefore is set at 1 million. 
235 new cases of MPC were found in the DRE study, and this is the number of cases 
dispersed in the simulated population. Although this number is known to be less than the actual 
number of people with MPC during the DRE data collection period, the simulation will analyze 
the estimation of the effect of DRE on applicable MPC according to the criteria for caseness in 
that study; there is the assumption of generalizability to more general MPC. 
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We must also consider the distribution of 1990 age. Although the DRE study sample was 
also matched on region, for simplicity we will match simulated samples only according to age 
and assume that the results extend to situations of more numerous strata. 
Table 4.1 Distribution of 5-year age group (in 1990) in the 2000/2001 DRE study population and 
sampled cases 
1990 Age Group 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70+ 
% Population 22.41 19.71 15.33 11.01 10.83 9.35 6.08 5.28 
% Sample cases 1.28 2.13 7.23 10.64 21.7 22.13 26.81 8.08 
Figure 4.1 Distribution of 5-year age group (in 1990) in the 2000/2001 DRE study population and 
sampled cases 
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Table 4.1 and Figure 4.1 show the distribution of 5-year age group in 1990 in the 
2000/2001 DRE study population and amongst the 235 sampled cases. Together these show a 
strong association between the cross-sectional risk of MPC and age; prevalence of new cases by 
age group increases monotonically until the 70+ group when it drops off, possibly because those 
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who would get MPC are likely to have it and have died before 80 years of age (70 in 1990). The 
distribution in the DRE study population was estimated using the Ontario portion of the 
2000/2001 Canadian Community Health Survey (CCHS), a cross-sectional Statistics Canada 
survey. 
These numbers are sufficient to estimate the appropriate age-specific prevalence of new 
cases for the simulated population. The number of cases and controls in the simulated population 
according to age group are obtained as follows for each age group i: 
Npn ii =  
)1(
ii apa =  (cases) 
iii anb −=  (controls) 
iii nar =  (age-specific prevalence) 
where  is the proportion of the DRE study population in age group i,  is the proportion of 
sampled cases in age group i, and a=235 cases. 
ip
)1(
ip
Cases in the simulated population were assigned a date of MPC diagnosis according to a 
uniform distribution between 10 and 12 years. Figure 4.2 shows that this approximately matches 
the distribution of MPC diagnosis in the DRE study data. 
 37
Figure 4.2 Distribution of time from 1990 to diagnosis of MPC in the DRE study cases (10 subjects 
within 2 months of 12 years are collapsed into bin [11.5,12]) 
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Event times can take on any distribution with a non-negative support. The survivor 
function S(t) is the probability of not having the event up to the time t. It equals the integral of the 
density from 0 to t, or 1 minus the CDF. Two distributions commonly used to describe event 
times are the exponential and Weibull. The exponential was the first widely recognized lifetime 
distribution, while the Weibull is thought by some to be the most widely used today [20]. The 
exponential density is: 
( ) tetf λλ −=  
while the Weibull density is: 
( ) ( ) ( ){ }βλβλλβ tettf −−= 1  
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The exponential is a special case of the Weibull where 1=β . λ  is the hazard rate in the 
exponential density and the rate parameter in the Weibull. β  is the shape parameter in the 
Weibull. It can be shown that if the exponential distribution fits the data then log(S(t)) should be 
linearly related to t, and if the Weibull distribution fits the data then log(-log(S(t)) should be 
linearly related to t. 
The exponential regression model is: 
( ) εβ += XTln  
where T is the event time and ε  is a random error term distributed according to the standard 
extreme value distribution [21]. λ  is estimated as . The Weibull regression model is: βλ X−= eˆ
( ) σεγ += XTln  
where σβ 1= , and again  with βλ X−= eˆ ε  a random error term distributed according to the 
standard extreme value distribution [21]. 
Rate of DRE screening in the DRE study data was modeled with both the exponential 
distribution and the more general Weibull and the former was found to fit the DRE study data 
equally well (LRT p-value=0.29). Further, Figure 4.3 shows that the plot of the log of the non-
parametric Kaplan-Meier survival curve [5] (stratified by case/control status) against time is 
reasonably straight. This indicates that the exponential distribution fits the time to first screening 
DRE reasonably well; we will use the exponential distribution to model DRE event times. 
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Figure 4.3 log(S(t)) versus t from the Kaplan-Meier survivor function for first screening DRE 
stratified by case/control status 
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The estimated hazard rate of DRE screening for controls in the DRE study data is 0.135 
per year. For the exponential distribution, the rate parameter is related to the probability of DRE 
over time according to the relationship: 
( ) ( )peSpP −−=⇒−=−== − 1ln
10
11)10(11999 and 1990between  DRE 10 λλ  
Solving this yields a probability of DRE in controls of 0.741 over ten years (the approximate 
duration of the data collection). Recall that the adjusted odds ratio in the study was 0.861. Letting 
this describe a ten-year odds ratio, and since odds ratios are symmetric, this implies a probability 
of DRE in cases of 0.711 between 1990 and 1999 according to the formula: 
00
0
1
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This in turn requires a rate of DRE in cases of 0.124 per year. Each case and control in the 
simulated population is assigned a random time to first DRE measured from 1990 according to 
the exponential distribution with the appropriate rate. 
Next we consider prostate-related symptoms. 26.2% of controls and 21.3% of cases in the 
DRE study data had symptoms at baseline. Subjects were assigned symptoms at baseline 
according to these probabilities. For the remaining subjects, exponential regression was used to 
estimate rates of symptoms in each third of the 1990 decade. These models fit as well as the 
Weibull (LRT p-value=0.16, 0.09, 0.78), and plots of log(S(t)) against t were reasonably straight. 
This produced the following rates of first symptoms onset for controls versus cases in each third 
of the decade: 0.0593 vs. 0.0588, 0.0815 vs. 0.0797, and 0.102 vs. 0.152. The steady increase 
from third to third reflects the effect of aging on the rate of symptoms. The more dramatic 
increase in symptoms in the third third amongst cases was expected; these are largely symptoms 
of PC. Time to first onset of symptoms was generated randomly for each simulated baseline-
asymptomatic subject according to these rates. If the first symptom did not appear in the first 
third then an event time was generated from 3 and 1/3 years using the rates for the second third. If 
that first symptom did not appear in the second third then an event time was generated from 6 and 
2/3 years using the rates for the third third, and this would be the time of first symptoms onset. 
Finally, we generate the reference date. In the DRE study, about 10% of cases who had a 
first DRE before their reference date were screen-detected by that DRE, which leaves 90% who 
were detected by other means. Thus for the simulation we must generate a competing diagnostic 
event. It is reasonable to suppose that time to diagnostic event is related to symptoms. Modeling 
time to competing diagnostic event as a function of symptoms in the DRE study data, we find that 
the Weibull model provides a better fit to the data than the exponential (LRT p-value<0.001), and 
the plot of log(-log(S(t)) against t is reasonably straight. The event parameters are λ =0.0905 and 
β =3.292 for asymptomatic time giving an expected time of 9.9 years, and λ =0.1433 and 
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β =1.642 for symptomatic time giving a (shorter) expected time of 6.2 years. Competing 
diagnostic event times were generated for each simulated case according to the appropriate 
distribution. If the asymptomatic event time exceeded the time of first symptoms onset, a new 
event time was generated from first symptoms onset with the symptomatic distribution. 
Diagnostic event times exceeding the date of MPC diagnosis were set equal to that date. 
Diagnostic event times were then compared to the first DRE for the simulated case. If the DRE 
happened before the diagnostic event, then with probability 0.1 the DRE detects the PC and the 
reference date is set to the earliest of the diagnostic event time and one month after the DRE (to 
allow time for biopsy). Otherwise, the reference date is set to the diagnostic event time. 
4.2 Drawing and analyzing a case-control sample 
The next step is to take a case-control sample from the simulated population. First, all 
235 cases are selected. Two controls are then randomly selected to match each case on the basis 
of age group. This sample is analyzed according to the method followed in the DRE study. For 
simplicity, age group is the sole matching variable. Also, no confounding variables are included 
in this simulation so the propensity score step is omitted. Thus, life tables are stratified only on 
age group, instead of age group, region and propensity score. Each analysis produces a Mantel-
Haenszel odds ratio and test-based confidence limits. 
4.3 Varying populations 
To properly study the performance of the method, it is necessary to simulate populations 
and analyses under a variety of conditions, not just those which match the parameters in the DRE 
study. Beginning with the population described in Section 4.1, several parameters were varied: 
the probability of screen-detection in cases given they had a screening test is set to 0.1, 0.5 and 
0.9; censoring versus no censoring (no symptoms); small (235 cases) versus larger (470 cases) 
case groups; and moderate true protective effect (ten-year OR=0.861) versus a strong effect 
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(0.500). In addition, more life table intervals (3 intervals with endpoints at 0, 3, 6 and 12 years) in 
the analysis was compared to fewer intervals (2 intervals with endpoints at 0, 6 and 12 years). 
This describes 24 populations in total, each analyzed 2 different ways. 
Each combination of population parameters describes "true" probabilities and rates. The 
actual effect observed in a given simulated population may appear quite different, however. Even 
if the true effect of DRE within the decade is 0.861 for example, in a given population one might 
observe an odds ratio of 1.1 or something else due to chance. The "true" effect actually describes 
a comparison of hazard rates and event probabilities between cases and controls. Any given group 
of cases and controls can exhibit observed DRE counts quite contrary to the expected counts; in 
one population cases may have more DREs, while in another controls will have more DREs. It is 
only through replication that the law of large numbers begins to ensure that "true" effects are seen 
in practice. Thus to assess the methodology, each combination of parameters should be used to 
generate many simulated populations and samples. From each combination of population 
parameters, 100 simulated populations are generated, and from each simulated population, 1 case-
control sample is drawn and analyzed with more (3) and fewer (2) life table intervals. This totals 
2,400 populations and case-control samples, and 4,800 analyses. 
4.4 Results 
The population odds ratio for each simulated population is calculated as the stratified 
Mantel-Haenszel case-control odds ratio on the full simulated population (PMHOR). In general, 
since observation time begins in 1990 and ends at censoring times that are not the same between 
cases and controls, PMHOR is not expected to equal the true odds ratio. It is desirable to confirm 
that in the absence of censoring the odds ratio would be right and therefore the relative driving 
force behind DRE processes for cases versus controls correctly warrants being described with the 
"true" ten-year odds ratio. The uncensored population odds ratio is calculated as the stratified 
Mantel-Haenszel case-control odds ratio on the full simulated population (UCPMHOR), counting 
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all DREs between 1990 and 1999 regardless of the censoring processes, symptoms and competing 
diagnostic events. UCPMHOR is expected to equal the true odds ratio. This is confirmed in each 
parameter combination by taking and back-transforming normal-based confidence limits about 
log-UCPMHOR using the 100 replicates, and checking that the limits for UCPMHOR contain the 
true odds ratio. 
The probability of a given screening test detecting the disease in a case (P(SD|DRE)) 
does not affect the odds ratios at the population level. This is because: a) cases and controls are 
not matched in the general population, so controls are unaffected by the earlier ending of 
observation time in cases; and b) the cases' DRE status is unaffected since all subjects who are 
possibly observed for a shorter time due to screen-detection will still have their DRE recorded 
just prior to detection. There are 8 combinations of the remaining population parameters that 
produce different population odds ratios. These are summarized inTable 4.2. 
Table 4.2 Mean simulated population odds ratios for the 8 population groups with distinct odds 
ratios, based on 300 replicates each, with 95% confidence intervals 
Pop #s 
True 
OR Cases 
Censor-
ing PMHOR 
95% CI 
PMHOR 
UC-
PMHOR 
95% CI UC-
PMHOR 
1-3 0.861 235 Yes 0.901 (0.881,0.906) 0.858 (0.834,0.863)
4-6 0.861 235 No 0.639 (0.623,0.643) 0.871 (0.846,0.876)
7-9 0.861 470 Yes 0.908 (0.896,0.914) 0.871 (0.857,0.876)
10-12 0.861 470 No 0.643 (0.634,0.647) 0.865 (0.852,0.871)
13-15 0.500 235 Yes 0.642 (0.626,0.646) 0.501 (0.488,0.504)
16-18 0.500 235 No 0.396 (0.387,0.398) 0.508 (0.496,0.511)
19-21 0.500 470 Yes 0.643 (0.632,0.647) 0.499 (0.492,0.502)
22-24 0.500 470 No 0.391 (0.385,0.393) 0.504 (0.497,0.508)
As expected, PMHOR does not equal (the 95% confidence intervals do not contain) the 
true odds ratio. Uncensored (asymptomatic) populations tend to underestimate it, while censored 
populations tend to overestimate it. The negative bias in PMHOR in the uncensored combinations 
is expected; controls are observed for the full ten years, while cases are only observed until the 
earliest of ten years and their competing diagnostic event, less than ten years on average. The 
positive bias in PMHOR in the censored combinations is because cases are observed for a longer 
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time; controls are censored at higher rates in the first 2/3 of the decade, and 26.2% (compared to 
21.3% of cases) are already symptomatic at baseline and have 0 person-time. The confidence 
limits around UCPMHOR confirm that in the absence of censoring, the true ten-year odds ratio is 
accurate in each population; the true odds ratio falls inside the confidence limits in all 8 factor 
combinations. 
A single case-control sample is drawn from each population and analyzed twice (with 
more and fewer intervals), each analysis producing a life table Mantel-Haenszel odds ratio 
(LTMHOR). For comparison, the usual (age) stratified Mantel-Haenszel case-control odds ratio is 
also produced (MHOR), which as explained in the introduction is expected to be biased when 
there are screen-detected cases. But censoring will also (unfairly, perhaps) bias the MHOR, due 
to the fact that controls and cases are censored at different rates and therefore have unequal 
opportunities to be screened from 1990 forward. Therefore another comparison odds ratio is also 
calculated, the even-time stratified Mantel-Haenszel case-control odds ratio (ETMHOR). This is 
obtained by taking the earliest censoring time in each matched set of three subjects and censoring 
all three at that time. There is some loss of person-time in this method. Test-based confidence 
limits are calculated for LTMHOR, and asymptotic limits are calculated for MHOR and 
ETMHOR. 
Conditional logistic regression (conditioning on the un-collapsed matching variable age 
group) was also used to analyze each sample as an alternative to MHOR as well as an even-time 
alternative to ETMHOR. The mean results were extremely close in all combinations to MHOR 
and ETMHOR (point estimates and confidence intervals equal to within 0.005 in all but one 
combination, which was equal to within 0.006). Therefore for brevity the conditional logistic 
regression results are omitted, and MHOR and ETMHOR are understood to represent both 
themselves and their conditional logistic regression counterparts. 
 45
4.4.1 Point estimates 
The mean sample odds ratios (with LTMHOR based on 3 life table intervals) are shown 
in Table 4.3 for all 24 factor combinations along with 95% confidence limits for the LTMHOR, 
calculated by taking and back-transforming normal-based confidence limits about log-LTMHOR 
using the 100 replicates. Between MHOR, ETMHOR and LTMHOR, the best estimator (closest 
mean estimate to the true odds ratio) is in bold in each row. 
Table 4.3 Mean sample odds ratios based on 100 replicates in each combination of parameters, life 
table odds ratio calculated with more (3) intervals; the closest mean estimate to the true 
odds ratio is in bold 
Pop 
# 
True 
OR 
Obs 
Time 
Corr 
True 
OR Cases
Cen-
sor-
ing 
P(SD| 
DRE) MHOR
ET-
MHOR
LT-
MHOR 
95% CI LT-
MHOR 
1 0.861 4.53 0.895 235 Yes 0.1 1.191 0.964 0.960 (0.919,0.977)
2 0.861 3.99 0.898 235 Yes 0.5 1.328 1.088 0.966 (0.925,0.984)
3 0.861 3.44 0.901 235 Yes 0.9 1.543 1.242 0.992 (0.948,1.011)
4 0.861 8.65 0.870 235 No 0.1 0.984 0.984 0.923 (0.895,0.939)
5 0.861 7.17 0.879 235 No 0.5 1.383 1.383 0.924 (0.894,0.939)
6 0.861 5.75 0.888 235 No 0.9 2.009 2.009 0.976 (0.940,0.994)
7 0.861 4.55 0.895 470 Yes 0.1 1.174 0.963 0.952 (0.930,0.966)
8 0.861 3.98 0.898 470 Yes 0.5 1.348 1.090 0.973 (0.948,0.988)
9 0.861 3.44 0.901 470 Yes 0.9 1.548 1.218 0.993 (0.967,1.008)
10 0.861 8.67 0.870 470 No 0.1 0.977 0.977 0.915 (0.900,0.926)
11 0.861 7.20 0.879 470 No 0.5 1.409 1.409 0.942 (0.924,0.954)
12 0.861 5.75 0.888 470 No 0.9 1.956 1.956 0.962 (0.941,0.976)
13 0.500 4.58 0.586 235 Yes 0.1 0.830 0.711 0.660 (0.630,0.673)
14 0.500 4.14 0.593 235 Yes 0.5 0.892 0.761 0.649 (0.615,0.662)
15 0.500 3.72 0.600 235 Yes 0.9 1.044 0.901 0.698 (0.668,0.711)
16 0.500 8.73 0.520 235 No 0.1 0.579 0.579 0.618 (0.599,0.629)
17 0.500 7.58 0.538 235 No 0.5 0.792 0.792 0.635 (0.613,0.646)
18 0.500 6.44 0.556 235 No 0.9 1.017 1.017 0.645 (0.624,0.656)
19 0.500 4.56 0.586 470 Yes 0.1 0.839 0.713 0.665 (0.647,0.675)
20 0.500 4.13 0.593 470 Yes 0.5 0.913 0.787 0.664 (0.645,0.675)
21 0.500 3.73 0.599 470 Yes 0.9 1.001 0.855 0.668 (0.649,0.679)
22 0.500 8.72 0.520 470 No 0.1 0.584 0.584 0.619 (0.607,0.627)
23 0.500 7.59 0.538 470 No 0.5 0.777 0.777 0.632 (0.618,0.640)
24 0.500 6.45 0.556 470 No 0.9 1.011 1.011 0.643 (0.630,0.652)
Besides the factors, also shown are mean observation time and a time-corrected true odds 
ratio. Mean observation time is the average time from 1990 to the earliest of the reference date 
and the censoring date in the samples drawn from each combination. The time-corrected true 
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odds ratio reflects the fact that when subjects are observed for less than ten years the odds ratio 
for an event changes, assuming rates of DRE remain constant in cases and controls. This is 
because the relative event probability between two groups with exponential event times and 
different hazard rates varies with observation time. Figure 4.4 illustrates the phenomenon; it 
shows that odds ratio is nearly linearly related to observation time between 1 and 10 years. 
Figure 4.4 Odds ratio as a function of observation time, when true ten-year odds ratio is 0.861 based 
on a hazard rate for DRE screening of 0.135 per year in controls and 0.124 per year in 
cases (left); and when true ten-year odds ratio is 0.500 based on a hazard rate for DRE 
screening of 0.135 per year in controls and 0.0887 per year in cases (right) 
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In 22 of 24 combinations (92%), Table 4.3 shows LTMHOR to have a closer mean 
estimate to the true odds ratio (less biased) than MHOR or ETMHOR. Populations 16 and 22, 
both with true ten-year odds ratios 0.500 (strong) and P(SD|DRE)=0.1, have mean MHOR and 
ETMHOR tied (since in uncensored populations samples matched on observation time already 
have "even time") and superior to LTMHOR. But these factor combinations may not even be 
realistic, since if a screening test is effective enough for so strong an odds ratio, it would most 
likely need to detect the disease in cases with greater than 10% probability. 
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Figure 4.5 Mean sample odds ratios based on 100 replicates in each combination of parameters, life 
table odds ratio calculated with more (3) intervals; left figures are from censored 
populations while right are uncensored (asymptomatic); top figures have true ten-year 
OR=0.861 while lower ones have true ten-year OR=0.500  
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The results are summarized graphically in Figure 4.5. ET235 and ET470 are the mean 
ETMHOR estimates from populations with 235 and 470 cases, respectively. LT235 and LT470 
are the mean LTMHOR estimates. OR235 and OR470 are the time-adjusted true odds ratios 
based on the average observation time in the samples. MHOR is not compared here because it is 
always equal to or worse than ETMHOR. The graph shows that LTMHOR is generally superior 
to ETMHOR. Only for a strong effect (OR=0.500) with P(SD|DRE)=0.1 is LTMHOR worse 
(more biased) than ETMHOR, which as mentioned before is an unrealistic combination. The 
plots show that as P(SD|DRE) increases, the bias in ETMHOR increases steeply. LTMHOR is 
also positively biased, but its bias's dependence on P(SD|DRE) is minimal. For analyzing 
powerful screening tests (represented on the plot as P(SD|DRE)=0.9) LTMHOR is highly 
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superior to ETMHOR. Sample size (number of cases) appears to have no systematic effect on the 
expected value of LTMHOR or ETMHOR. Censoring processes slightly increase the bias in 
LTMHOR, uniformly across P(SD|DRE). For ETMHOR, censoring has a mitigating effect, 
worsening relatively good estimates at the low end of P(SD|DRE) (0.1) and improving terribly 
biased estimates at the high end (0.9). The improvement in ETMHOR for higher P(SD|DRE) 
results from censoring reducing the apparent dependence between the observation time for 
matched sets and the DRE events in their cases, by randomly omitting a subset of the DREs in 
screen-detected cases. This is not enough to eliminate the greater bias in ETMHOR over that of 
LTMHOR, however. As explained earlier, the "true" odds ratio is based on the ten-year event 
probabilities of DRE screening. That the time-adjusted true odds ratios increases with P(SD|DRE) 
is no surprise; controls are matched to cases on observation time, and detecting more cases with 
screening results in less observation time for everyone. Comparing the time-adjusted odds ratios 
to LTMHOR, most of the increase in the LTMHOR's bias with increasing P(SD|DRE) is 
eliminated. Unfortunately there remains some baseline residual bias even above the time-adjusted 
odds ratio, but this is small compared with ETMHOR, and conservative. 
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 Table 4.4 Mean sample odds ratios based on 100 replicates in each combination of parameters, life 
table odds ratio calculated with fewer (2) intervals; the closest mean estimate to the true 
odds ratio is in bold 
Pop 
# 
True 
OR 
Obs 
Time 
Corr 
True 
OR Cases
Cen-
sor-
ing 
P(SD| 
DRE) MHOR
ET-
MHOR
LT-
MHOR 
95% CI LT-
MHOR 
1 0.861 4.53 0.895 235 Yes 0.1 1.191 0.964 1.018 (0.973,1.038)
2 0.861 3.99 0.898 235 Yes 0.5 1.328 1.088 1.079 (1.032,1.099)
3 0.861 3.44 0.901 235 Yes 0.9 1.543 1.242 1.163 (1.109,1.186)
4 0.861 8.65 0.870 235 No 0.1 0.984 0.984 0.925 (0.890,0.942)
5 0.861 7.17 0.879 235 No 0.5 1.383 1.383 0.968 (0.930,0.986)
6 0.861 5.75 0.888 235 No 0.9 2.009 2.009 1.095 (1.044,1.116)
7 0.861 4.55 0.895 470 Yes 0.1 1.174 0.963 1.013 (0.988,1.029)
8 0.861 3.98 0.898 470 Yes 0.5 1.348 1.090 1.081 (1.051,1.098)
9 0.861 3.44 0.901 470 Yes 0.9 1.548 1.218 1.162 (1.128,1.181)
10 0.861 8.67 0.870 470 No 0.1 0.977 0.977 0.914 (0.896,0.926)
11 0.861 7.20 0.879 470 No 0.5 1.409 1.409 0.989 (0.966,1.004)
12 0.861 5.75 0.888 470 No 0.9 1.956 1.956 1.073 (1.044,1.090)
13 0.500 4.58 0.586 235 Yes 0.1 0.830 0.711 0.695 (0.661,0.708)
14 0.500 4.14 0.593 235 Yes 0.5 0.892 0.761 0.710 (0.670,0.724)
15 0.500 3.72 0.600 235 Yes 0.9 1.044 0.901 0.787 (0.750,0.803)
16 0.500 8.73 0.520 235 No 0.1 0.579 0.579 0.588 (0.567,0.599)
17 0.500 7.58 0.538 235 No 0.5 0.792 0.792 0.627 (0.602,0.639)
18 0.500 6.44 0.556 235 No 0.9 1.017 1.017 0.661 (0.635,0.673)
19 0.500 4.56 0.586 470 Yes 0.1 0.839 0.713 0.700 (0.680,0.711)
20 0.500 4.13 0.593 470 Yes 0.5 0.913 0.787 0.722 (0.700,0.735)
21 0.500 3.73 0.599 470 Yes 0.9 1.001 0.855 0.750 (0.726,0.764)
22 0.500 8.72 0.520 470 No 0.1 0.584 0.584 0.591 (0.578,0.599)
23 0.500 7.59 0.538 470 No 0.5 0.777 0.777 0.623 (0.608,0.632)
24 0.500 6.45 0.556 470 No 0.9 1.011 1.011 0.659 (0.643,0.668)
 50
Figure 4.6 Mean sample odds ratios based on 100 replicates in each combination of parameters, life 
table odds ratio calculated with fewer (2) intervals; left figures are from censored 
populations while right are uncensored (asymptomatic); top figures have true ten-year 
OR=0.861 while lower ones have true ten-year OR=0.500 
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Next we consider analyses based on 2 life table intervals. Table 4.4 and Figure 4.6 
summarize the results. Censoring has a greater impact on the bias than it did with 3 intervals. In 
the (unrealistic) combination with true odds ratio 0.500 and P(SD|DRE)=0.1, fewer life table 
intervals actually improved LTMHOR under no censoring. However, in general LTMHOR is 
more biased when based on fewer intervals. But even so, LTMHOR is generally superior to 
ETMHOR, with the closer mean estimate in 20/24 combinations (83%). 
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4.4.2 Coverage probabilities 
Finally we consider coverage probabilities (CPs) of the 95% confidence intervals for 
sample odds ratios. CP is estimated as the average of an indicator variable for the confidence 
limits containing the true odds ratio. 
Table 4.5 Coverage probabilities of 95% confidence intervals for sample odds ratios based on 100 
replicates in each combination of parameters, life table odds ratio calculated with more 
(3) intervals; the closest CP to 0.95 is in bold 
Pop 
# 
True 
OR 
Obs 
Time 
Corr 
True 
OR Cases
Cen-
sor-
ing 
P(SD| 
DRE)
Covg 
Prob 
MHOR
Covg 
Prob 
ET-
MHOR
Covg 
Prob 
LT-
MHOR 
95% CI 
Covg Prob 
LT-MHOR 
1 0.861 4.53 0.895 235 Yes 0.1 0.51 0.97 0.90 (0.824,0.936)
2 0.861 3.99 0.898 235 Yes 0.5 0.31 0.86 0.89 (0.824,0.936)
3 0.861 3.44 0.901 235 Yes 0.9 0.08 0.69 0.86 (0.800,0.921)
4 0.861 8.65 0.870 235 No 0.1 0.88 0.88 0.91 (0.848,0.951)
5 0.861 7.17 0.879 235 No 0.5 0.24 0.24 0.90 (0.836,0.944)
6 0.861 5.75 0.888 235 No 0.9 0.01 0.01 0.87 (0.800,0.921)
7 0.861 4.55 0.895 470 Yes 0.1 0.24 0.94 0.91 (0.848,0.951)
8 0.861 3.98 0.898 470 Yes 0.5 0.02 0.69 0.83 (0.753,0.890)
9 0.861 3.44 0.901 470 Yes 0.9 0.00 0.43 0.83 (0.753,0.890)
10 0.861 8.67 0.870 470 No 0.1 0.83 0.83 0.93 (0.874,0.965)
11 0.861 7.20 0.879 470 No 0.5 0.01 0.01 0.92 (0.861,0.958)
12 0.861 5.75 0.888 470 No 0.9 0.00 0.00 0.83 (0.753,0.890)
13 0.500 4.58 0.586 235 Yes 0.1 0.16 0.77 0.63 (0.477,0.659)
14 0.500 4.14 0.593 235 Yes 0.5 0.11 0.60 0.66 (0.497,0.678)
15 0.500 3.72 0.600 235 Yes 0.9 0.03 0.34 0.51 (0.350,0.533)
16 0.500 8.73 0.520 235 No 0.1 0.89 0.89 0.70 (0.517,0.697)
17 0.500 7.58 0.538 235 No 0.5 0.25 0.25 0.59 (0.447,0.631)
18 0.500 6.44 0.556 235 No 0.9 0.03 0.03 0.54 (0.398,0.582)
19 0.500 4.56 0.586 470 Yes 0.1 0.02 0.44 0.26 (0.169,0.325)
20 0.500 4.13 0.593 470 Yes 0.5 0.00 0.25 0.33 (0.204,0.368)
21 0.500 3.73 0.599 470 Yes 0.9 0.01 0.11 0.34 (0.212,0.379)
22 0.500 8.72 0.520 470 No 0.1 0.76 0.76 0.37 (0.195,0.357)
23 0.500 7.59 0.538 470 No 0.5 0.06 0.06 0.26 (0.160,0.314)
24 0.500 6.45 0.556 470 No 0.9 0.00 0.00 0.25 (0.110,0.247)
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Figure 4.7 Coverage probabilities of 95% confidence intervals for sample odds ratios based on 100 
replicates in each combination of parameters, life table odds ratio calculated with more 
(3) intervals; left figures are from censored populations while right are uncensored 
(asymptomatic); top figures have true ten-year OR=0.861 while lower ones have true ten-
year OR=0.500 
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Coverage probabilities from the analyses based on 3 life table intervals are summarized 
in Table 4.5 and Figure 4.7. In 18/24 combinations (75%), LTMHOR has a CP closer to 95% 
than ETMHOR. CP tends to be worse as the point estimates become more biased, which makes 
obvious sense. For a more extreme effect (odds ratio=0.500), CP suffers compared with a milder 
odds ratio (0.861); but in terms of relative odds ratios this is also in line with what was observed 
in the point estimates. Censoring appears to have no systematic effect on the CPs for LTMHOR, 
but once again for ETMHOR it is a mitigating influence; higher CPs are lowered and lower ones 
are raised. This is again in line with the bias of the point estimates. Note that smaller case groups 
(235 cases) improve the coverage probability for both LTMHOR and ETMHOR especially under 
a stronger effect, even though the point estimates were generally close. This is because if two 
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point estimates are equally biased, a wider confidence interval about the estimate will have better 
coverage probability for the true value than a narrower one. 
It can be noted that CP for LTMHOR is high in both the censored and uncensored groups 
when the true odds ratio is 0.861. In those groups it is about 90% except when P(SD|DRE) is 
most extreme (0.9). This reflects well on the DRE study. In the absence of the small positive bias 
in LTMHOR the coverage would probably be close to 95%, indicating that Miettinen's test-based 
limits are performing well. 
Table 4.6 Coverage probabilities of 95% confidence intervals for sample odds ratios based on 100 
replicates in each combination of parameters, life table odds ratio calculated with fewer 
(2) intervals; the closest CP to 0.95 is in bold 
Pop 
# 
True 
OR 
Obs 
Time 
Corr 
True 
OR Cases
Cen-
sor-
ing 
P(SD| 
DRE)
Covg 
Prob 
MHOR
Covg 
Prob 
ET-
MHOR
Covg 
Prob 
LT-
MHOR 
95% CI 
Covg Prob 
LT-MHOR 
1 0.861 4.53 0.895 235 Yes 0.1 0.51 0.97 0.87 (0.800,0.921)
2 0.861 3.99 0.898 235 Yes 0.5 0.31 0.86 0.79 (0.708,0.857)
3 0.861 3.44 0.901 235 Yes 0.9 0.08 0.69 0.72 (0.632,0.796)
4 0.861 8.65 0.870 235 No 0.1 0.88 0.88 0.94 (0.861,0.958)
5 0.861 7.17 0.879 235 No 0.5 0.24 0.24 0.85 (0.776,0.906)
6 0.861 5.75 0.888 235 No 0.9 0.01 0.01 0.66 (0.569,0.743)
7 0.861 4.55 0.895 470 Yes 0.1 0.24 0.94 0.82 (0.753,0.890)
8 0.861 3.98 0.898 470 Yes 0.5 0.02 0.69 0.62 (0.528,0.706)
9 0.861 3.44 0.901 470 Yes 0.9 0.00 0.43 0.40 (0.313,0.493)
10 0.861 8.67 0.870 470 No 0.1 0.83 0.83 0.93 (0.874,0.965)
11 0.861 7.20 0.879 470 No 0.5 0.01 0.01 0.80 (0.719,0.865)
12 0.861 5.75 0.888 470 No 0.9 0.00 0.00 0.55 (0.457,0.640)
13 0.500 4.58 0.586 235 Yes 0.1 0.16 0.77 0.61 (0.487,0.669)
14 0.500 4.14 0.593 235 Yes 0.5 0.11 0.60 0.52 (0.408,0.592)
15 0.500 3.72 0.600 235 Yes 0.9 0.03 0.34 0.36 (0.248,0.421)
16 0.500 8.73 0.520 235 No 0.1 0.89 0.89 0.88 (0.812,0.929)
17 0.500 7.58 0.538 235 No 0.5 0.25 0.25 0.73 (0.632,0.796)
18 0.500 6.44 0.556 235 No 0.9 0.03 0.03 0.55 (0.457,0.640)
19 0.500 4.56 0.586 470 Yes 0.1 0.02 0.44 0.23 (0.152,0.303)
20 0.500 4.13 0.593 470 Yes 0.5 0.00 0.25 0.21 (0.135,0.281)
21 0.500 3.73 0.599 470 Yes 0.9 0.01 0.11 0.14 (0.079,0.200)
22 0.500 8.72 0.520 470 No 0.1 0.76 0.76 0.68 (0.579,0.752)
23 0.500 7.59 0.538 470 No 0.5 0.06 0.06 0.43 (0.341,0.523)
24 0.500 6.45 0.556 470 No 0.9 0.00 0.00 0.28 (0.204,0.368)
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 Figure 4.8 Coverage probabilities of 95% confidence intervals for sample odds ratios based on 100 
replicates in each combination of parameters, life table odds ratio calculated with fewer 
(2) intervals; left figures are from censored populations while right are uncensored 
(asymptomatic); top figures have true ten-year OR=0.861 while lower ones have true ten-
year OR=0.500 
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Coverage probabilities from the analyses based on 2 life table intervals are summarized 
in Table 4.6 and Figure 4.8. In only 13/24 combinations (54%), LTMHOR has a CP closer to 
95% than ETMHOR. However, the graph shows that controlling for sample size, LTMHOR tends 
to win big when it wins, compared with an only moderately better ETMHOR when that performs 
best. Again, CP sensibly tends to be worse as the point estimates become more biased. Censoring 
has a greater impact on CP for LTMHOR than when LTMHOR was based on 3 intervals, which 
is also what was observed in the point estimates. 
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In the context of the DRE study, it can be noted that the CP for LTMHOR remains high 
in both the censored and uncensored groups when the true odds ratio is 0.861 and P(SD|DRE) is 
moderate (0.1). The DRE study did even better, based on more (3) life table intervals. 
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5 CHAPTER FIVE:  
DISCUSSION AND CONCLUSION 
The life table Mantel-Haenszel odds ratio (LTMHOR) developed in this study provides a 
better estimate of the odds ratio from case-control screening data than previous methods used in 
this area. Although there is some residual bias, it is relatively small and in the conservative 
direction. On the other hand, the time-adjusted Mantel-Haenszel odds ratio (ETMHOR) 
alternative is extremely biased, and the bias increases steeply with the probability that a screened 
case is detected by the test. Unfortunately, the more efficacious a screening test is, the higher this 
proportion will be in general, and the more biased the results. Conditional logistic regression as 
an alternative to MHOR does not improve matters. The fundamental problem with using these 
estimators on case-control screening data is the dependence between screening tests in screen-
detected cases and the end of the observation time in their matched controls. Stopping the 
observation time in controls immediately after a screening test is counted in the case is a perfect 
design for recording as many screening tests in cases as possible while minimizing those counted 
in controls. 
LTMHOR solves this problem with its approach to censoring. Estimates are based on life 
table event probabilities in cases versus controls, and the life table is constructed to handle 
censoring appropriately (as long as that censoring is non-informative). To assess whether this is 
reasonable, consider each censoring process. Firstly, for controls, the reference date (date of 
diagnosis in the matched case) forms an independent censoring process from screening tests in 
the control because the case and control are unconnected and unaware of each other. 
Symptomatic progression in controls, the other censoring process, also runs independently of 
screening tests, because in the absence of symptoms, a test marked as screening probably is—but 
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what about as a control nears the onset of symptoms? If the first symptoms are about to appear in 
a few months, can that affect the rate of screening DREs? Since the symptoms have not yet 
appeared, the answer should be no. Next we consider censoring processes for cases. It is assumed 
for cases that the competing diagnosis of PC (non-DRE-detected PC) is a process that runs 
independently of screening DREs. In non-screen-detected cases who do not develop symptoms, 
the reasoning is that there are no outward indications that could influence frequency of screening 
DREs. Symptomatic progression in cases is a separate censoring process, and a non-informative 
one by an argument analogous to that given for controls. 
There are alternative survival analysis methods that might have been considered instead 
of the life table. One might try continuous time approaches rather than the discetized life table, 
for example fitting parametric regression models such as piecewise Weibull or exponential, then 
calculating an odds ratio to describe the difference in event probabilities over different lengths of 
time. One of the reasons for using the life table in this study was that there is some scientific 
literature using this approach at least to describe the effect of an exposure in stratified prospective 
data. While this project went further by applying this to the retrospective, case-control situation 
and then reversed the interpretation of the odds ratio, this is less of a leap than might otherwise 
have been the case had we fit continuous time models and proceeded from there. In trying to 
publish scientific results, smaller leaps are more readily accepted than giant ones, in part because 
smaller leaps tend to lead to fewer mistakes. Still another approach might have been the log rank 
test to assess if two curves differ. While this would have provided a p-value, it does not naturally 
lead to an estimate of the odds ratio, which was desired in this study. 
There are also alternative general approaches other than survival analysis that might have 
been developed for this problem. During this study some were considered. One approach would 
have been to begin with a 2 by 2 table crossing DRE with case/control status, then adjust the cell 
sizes to reflect the estimated effects of dependence bias. The adjustment would incorporate an 
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estimate of when screen-detected cases would have been diagnosed had they not been detected by 
a DRE, and how that additional observation time would have altered the DRE counts in matched 
controls. This is a very novel approach that would have suffered from weaker scientific 
background (i.e., no backing in literature). Still another approach might have involved estimating 
a DRE rate ratio, which would directly estimate and compare rates of DRE between cases and 
controls rather than modeling time to first DRE. While rate of DRE might actually be the more 
appropriate measure considering that one single DRE in a lifetime will probably not help you 
very much, again it does not naturally reverse itself into an estimate for the effect of DRE on the 
odds of MPC. Further, time to first DRE perhaps serves well as a proxy for rate of DRE, if it can 
be assumed that shorter time to first DRE indicates a higher rate of DRE throughout a lifetime. In 
any case, these alternatives and others may be explored more fully in the future and better 
solutions may be found, such is the case with all science. 
LTMHOR performs better than ETMHOR, but considering how poorly ETMHOR 
performs this is perhaps nothing to brag about. Considering instead how LTMHOR performs in 
its own right, it does provide good estimates (not too biased) under various combinations of true 
ten-year odds ratio, screen-detection probability for cases, censoring or not beyond that due to the 
competing diagnostic event (and/or the reference date in controls), and smaller or larger case 
groups. Miettinen's test-based limits provide good coverage probability when the true odds ratio 
is moderate and the case group is not too large. But that said, there is room for improvement. That 
the life table Mantel-Haenszel odds ratio remains slightly biased might form the basis of 
additional work in this area. In the meantime, that the bias is small and (importantly) in the 
conservative direction bodes well for both the results of the current DRE study and others like it 
in the future that might make use of this estimator. 
In this study, the life table Mantel-Haenszel odds ratio describing the effect of having a 
screening DRE on the odds of MPC, after adjusting for the matched case-control design as well 
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as several potentially confounding variables, is 0.861 with 95% confidence interval (0.611, 
1.215). This constitutes only weak evidence of a mild protective effect of screening with digital 
rectal exam in the prevention of metastatic prostate cancer. However, considering that the 
simulation indicates a small positive bias in LTMHOR, and the fact that several previous studies 
also found mildly protective (if statistically insignificant) results, continued screening with DRE 
is advised at least until a more definitive study is undertaken. 
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